Announcements

We are pleased to announce that the website of the MDPI Sustainability Foundation has been revamped! For the past couple of months, our UX UI team and front-end developers have been working hard to launch the website in time for the opening of the Sustainability Awards nominations.

The website is not the only thing that has had a remodeling. Indeed, the format of the Emerging Sustainability Leader Award (ESLA) has been updated. ESLA is now a competition open to individual researchers or start-ups founded by researchers under the age of 35. Nominee applications will go through 2 rounds of selection until the final 3 are decided. The finalists will then be invited to give pitch presentations during the Award Ceremony to win either first place (10,000 USD) or runner-up (2 x 5000 USD).

The World Sustainability Award, on the other hand, remains the same: a total prize money of 100,000 USD is up for grabs by senior individual researchers or groups of researchers from the international research community.

Nominations for both the World Sustainability Award and the Emerging Sustainability Leader award are now open! Check out our new website for more information on how to nominate.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Drug Development”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Drug Development”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Metastasis”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Metastasis”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

A range of MDPI journals will be attending the 15th Annual Meeting of Chinese Society for Immunology. This meeting will be held in Chongqing, China, from 27 to 30 December 2022.

The conference focuses on the following areas:

• Recognition and regulation of innate immune responses;
• Adaptive immune response;
• Immune metabolism and immune regulation;
• Immunity to COVID-19 infection;
• Tumor immunity and tumor immunotherapy;
• Autoimmune diseases and other topics.

The following MDPI journals will be represented:

• IJMS (leading journal);
• Vaccines;
• Metabolites;
• Cells;
• Cancers;
• Biomedicines;
• CIMB;
• Pathogens;
• Immuno.

If you plan on attending this conference, feel free to stop by our booth #B13. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please see the following link: https://csimeeting2022.sciconf.cn/cn/web/index/13562.  

Lung cancer is the most common malignancy in many parts of the world. It is often diagnosed late and has one of the poorest outcomes among other cancers. Recent studies (NELSON from Europe and NLST from USA) have shown that lung cancer screening via computed tomography scans can identify lung cancer at an earlier stage in certain populations, and reduce mortality. The diagnosis and management of these tumors, with many being small nodules or ground glass changes, remain a challenge. The landscape and management of lung cancer in general have also changed dramatically in the last decade, perhaps more than any other thoracic disease. Advances in surgery and cancer genetics facilitate personalized drug therapies that can provide ever more complex and innovative treatment algorithms to fight this terrible disease. The role of liquid biopsies, more targeted bespoke drug therapies, non-invasive endoscopic treatments, and high-precision surgeries are only some of the evolving horizons in lung cancer management.

November 2022 is designated as "World Lung Cancer Awareness Month", with various global activities that highlight and increase awareness of lung cancer for research support and development. We would like to share some of the high-quality and innovative research findings published in Cancers (ISSN: 2072-6694).

The list of relevant papers can be seen below:

“The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells”
by Dong Young Kang, Nipin Sp, Eun Seong Jo, Alexis Rugamba, Dae Young Hong, Hong Ghi Lee, Ji-Seung Yoo, Qing Liu, Kyoung-Jin Jang and Young Mok Yang
Available online: https://www.mdpi.com/2072-6694/12/3/727

“Extracellular Vesicle lincRNA-p21 Expression in Tumor-Draining Pulmonary Vein Defines Prognosis in NSCLC and Modulates Endothelial Cell Behavior”
by Joan J. Castellano, Ramon M. Marrades, Laureano Molins, Nuria Viñolas, Jorge Moises, Jordi Canals, Bing Han, Yan Li, Daniel Martinez, Mariano Monzó et al.
Available online: https://www.mdpi.com/2072-6694/12/3/734

“Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient”
by Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1125

“¹⁸F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival”
by Giulia Polverari, Francesco Ceci, Valentina Bertaglia, Maria Lucia Reale, Osvaldo Rampado, Elena Gallio, Roberto Passera, Virginia Liberini, Paola Scapoli, Vincenzo Arena et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1163

“Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with Lymph Node Status and Overall Survival”
by Francesca Botta, Sara Raimondi, Lisa Rinaldi, Federica Bellerba, Federica Corso, Vincenzo Bagnardi, Daniela Origgi, Rocco Minelli, Giovanna Pitoni, Francesco Petrella et al.
Available online: https://www.mdpi.com/2072-6694/12/6/1432

“Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab”
by Romain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann et al.
Available online: https://www.mdpi.com/2072-6694/12/8/2234

“Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study”
by Pierre-Jean Lamy, Paul van der Leest, Nicolas Lozano, Catherine Becht, Frédérique Duboeuf, Harry J. M. Groen, Werner Hilgers, Nicolas Pourel, Naomi Rifaela, Ed Schuuring et al.
Available online: https://www.mdpi.com/2072-6694/12/10/3002

“Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies”
by Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow and Giandomenico Roviello
Available online: https://www.mdpi.com/2072-6694/12/11/3293

“A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC”
by Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson and Bilal Piperdi
Available online: https://www.mdpi.com/2072-6694/12/12/3648

“Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review”
by Alice Indini, Erika Rijavec and Francesco Grossi
Available online: https://www.mdpi.com/2072-6694/13/8/1794

You are welcome to submit relevant papers to the Special Issue “World Lung Cancer Awareness Month”.

Dr. Calvin Sze Hang Ng
Editorial Board Member of Cancers

Stanford University has recently published an update of the list of the top 2% most widely cited scientists. The time node of the statistical data of this list is from 1960 to 2022, and it is divided into two lists: "Lifetime Scientific Influence Ranking" and "2022 Annual Scientific Influence Ranking". The "Lifetime Scientific Influence Ranking" counts the comprehensive influence performance of scientists during their careers, and the "2022 Annual Influence Ranking" focuses on highlighting the academic influence of scientists in the previous year. This ranking, considered the most prestigious worldwide, is based on the bibliometric information contained in the Scopus database and includes more than 200,000 researchers from the more than 10 million scientists considered to be active worldwide, with 22 scientific fields and 176 subfields taken into account.

We are pleased to share that 670 Editorial Board Members from MDPI’s Cancers (ISSN: 2072-6694) were featured in Stanford University World’s Top 2% Scientists list in 2022.

The latest Stanford rankings reflect the significant influence and research excellence of the scientists, who are committed to furthering their knowledge for the benefit of the world.

We would like to congratulate our Editorial Board Members on their excellent achievement and thank them for their immense contribution to the scientific progression and development of Cancers. 

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Pediatric Oncology”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Pediatric Oncology”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Cancer Informatics and Big Data”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Cancer Informatics and Big Data”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.

MDPI will be attending the 27th Congress of the Chinese Pediatric Society, held in Changsha, China, from 15–18 December 2022.

The following MDPI journals will be represented:

• Children (leading journal);
• JPM;
• Medicina;
• Audiology Research;
• JCM;
• Healthcare;
• Diagnostics;
• Metabolites;
• Cancers;
• Nutrients. 

If you plan on attending this conference, feel free to stop by our booth: #B67. Our delegates look forward to meeting you in person to answer any questions that you may have. 

For more information about the conference, please see the following link: https://nccps2022.tiemeeting.com/CN.

Cancers (IF: 6.575, ISSN: 2072-6694), a peer-reviewed and open access journal, is now recruiting Editorial Board Members (EBMs) for the Section “Infectious Agents and Cancer”.

The responsibilities of Section Editorial Board Members are as follows:

• Prescreening and making decisions on new submissions related to your research interests;
• Setting up at least one Special Issue during your term on a topic related to your research interests (or supervising Special Issues related to your research field);
• Providing input or feedback regarding journal policies;
• Helping to promote the journal among your peers or at conferences;
• Attending board meetings to suggest journal development strategies;
• Reviewing manuscripts.

For the full list of Editorial Board Members, please visit the following link: https://www.mdpi.com/journal/cancers/editors.

If you are interested in becoming a Section Editorial Board Member of the Cancers Section “Infectious Agents and Cancer”, please send us your full academic CV and a short cover letter detailing your interest in and suitability for the position. If you would like to recommend potential candidates or request further information, please contact the Cancers Editorial Office at cancers@mdpi.com. We look forward to working with you in the future.